
|Articles|July 1, 2004
Genaera begins more squalamine trials
Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement




























